JointBrex Official Website › Joint Supplement Guide
Joint Supplement GuideThe Joint Supplement Guide: What The Evidence Supports
Glucosamine and chondroitin have the largest evidence base in this aisle and the most argued-about results; boswellia has the most favourable recent meta-analysis; turmeric needs an amount most capsules cannot hold. Both current guidelines put exercise and weight management first, and neither of those comes in a bottle.
What is genuinely known, what is contested, and what the two guideline committees concluded after weighing it.
The joint-supplement argument nobody has settled
Glucosamine and chondroitin have been tested more thoroughly than almost any other supplement pair, and the results still disagree with each other. That is unusual and it is worth understanding, because it explains why every guideline position on them sounds so hedged.
The GAIT trial randomised 1,583 adults with knee osteoarthritis in the United States to glucosamine hydrochloride, chondroitin sulfate, both, celecoxib or placebo. Its overall result was negative for the supplements; a prespecified subgroup with moderate-to-severe pain did better on the combination, which is the kind of finding that generates twenty years of argument.
In Europe, three-year trials of glucosamine sulfate — a different salt, from a single manufacturer, at 1,500 mg once daily — reported slower joint-space narrowing. Supporters point to the salt and the dosing schedule; critics point to who funded them. MOVES then compared 1,500 mg of glucosamine with 1,200 mg of chondroitin against celecoxib and reported non-inferiority at six months in people with severe knee pain.
The Cochrane review of chondroitin describes the body of evidence as low quality, with small effects that shrink as trial quality rises. The Cochrane review of glucosamine reaches a similar place.
Both ingredients are well tolerated, both have been studied at 1,500 mg and 800–1,200 mg a day respectively, and the honest summary is that the effect, if it exists, is small and slow. Anyone buying them should buy them at the studied amounts, expect weeks rather than days, and not spend money they would miss.
Where the joint-supplement botanicals sit
| Ingredient | Best current evidence | Amount used | How confident |
|---|---|---|---|
| Boswellia serrata extract | A 2024 systematic review and meta-analysis in knee osteoarthritis, and a 2026 network meta-analysis against turmeric. | 100–250 mg a day of characterised extract | The most favourable recent evidence of any botanical in this aisle. |
| Turmeric / curcumin | A 2016 meta-analysis of randomised trials in arthritis. | About 1,000 mg a day of curcumin, usually with an absorption enhancer | Reasonable at that amount, which few capsules can hold. |
| MSM | A pilot randomised trial in knee osteoarthritis and a safety review. | 1.5–6 g a day | Promising and under-powered. Well tolerated. |
| Bromelain | Two randomised trials in knee osteoarthritis and a 2025 enzyme combination crossover trial. | 800 mg a day | Small trials, consistent direction. |
| Quercetin | One randomised trial, in rheumatoid arthritis. | 500 mg a day for eight weeks | Thin, and in a different disease. |
| Methionine | None for a joint outcome. The studied molecule is S-adenosylmethionine. | 600–1,200 mg a day of S-adenosylmethionine, not methionine | The two are routinely confused and should not be. |
Amount used is the daily amount in the trials cited, not a recommendation.
Two things fall out of that table. The first is that boswellia is underrated in a category that markets glucosamine hardest. The second is that most botanical amounts in multi-ingredient capsules are well below these numbers, for the simple physical reason that two capsules hold about 1,400 mg in total.
What the joint-supplement guidelines actually say
Two committees have weighed this evidence formally and published the result. Both are worth reading before spending anything in this aisle, and both say something the aisle would rather they did not.
The 2019 ACR and Arthritis Foundation guideline
Strongly recommends exercise for hand, hip and knee osteoarthritis, and weight loss for knee and hip osteoarthritis in people who are overweight. It recommends against glucosamine and against chondroitin.
The 2019 OARSI guideline
Covers non-surgical management of knee, hip and polyarticular osteoarthritis. Its core recommendations are exercise, weight management and self-management education. It does not recommend glucosamine or chondroitin either.
What that does and does not mean
It means the committees did not find the evidence convincing enough to recommend. It does not mean the ingredients are unsafe, and it does not mean nobody experiences benefit. It does mean an honest joint-supplement page has to print it.
The two joint interventions with the best evidence
Neither of them is sold in a bottle, which is precisely why they belong on a page published by a company that sells bottles.
| Intervention | Evidence | What it asks of you |
|---|---|---|
| Supervised exercise | A Cochrane review of exercise for knee osteoarthritis found moderate-quality evidence of reduced pain and improved physical function immediately after treatment. | Time, and usually a physiotherapist for the first few sessions. Free or cheap. |
| Weight management where weight is a factor | The IDEA trial and its three-and-a-half-year follow-up tracked knee pain against changes in body weight in adults with knee osteoarthritis. | The hardest of the two, and the one with the longest-lasting effect. |
Both are recommended by the ACR and OARSI guidelines above. Neither is a product.
A supplement can sit alongside both. It cannot replace either, and a page that did not say so would be selling something other than information.
How a joint-supplement buyer should use all of this
- Decide what you want the bottle to contain, then find one that prints the amount rather than hiding it in a blend.
- Buy the lead ingredient at or near its studied amount if you are buying it at all.
- Expect weeks. Every trial in this field dosed for eight weeks to three years before measuring anything.
- Read the allergen line. In this category it is not a formality.
- Keep the refund window and the pack size in the same sentence.
- And do the two things the guidelines recommend first, because they are free and they are better evidenced than anything on the shelf.
The worked example of all of this on one specific bottle is the JointBrex panel page, and the eight checks in order are in the other guide.
What this joint-supplement guide read
Eighteen sources, which is most of what this website cites.
- Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795-808. PMID 16495392. https://pubmed.ncbi.nlm.nih.gov/16495392/
- Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;(2):CD002946. PMID 15846645. https://pubmed.ncbi.nlm.nih.gov/15846645/
- Reginster JY, Deroisy R, Rovati LC, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251-6. PMID 11214126. https://pubmed.ncbi.nlm.nih.gov/11214126/
- Singh JA, Noorbaloochi S, MacDonald R, et al. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015;1:CD005614. PMID 25629804. https://pubmed.ncbi.nlm.nih.gov/25629804/
- Hochberg MC, Martel-Pelletier J, Monfort J, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016;75(1):37-44. PMID 25589511. https://pubmed.ncbi.nlm.nih.gov/25589511/
- Dalmonte T, Andreani G, Rudelli C, Isani G. Efficacy of Extracts of Oleogum Resin of Boswellia in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Phytother Res. 2024;38(12):5672-5689. PMID 39314013. https://pubmed.ncbi.nlm.nih.gov/39314013/
- Inprasit C, Bunyamahote S, Boonpattharatthiti K, et al. Evaluating the efficacy and safety of Curcuma longa, Boswellia serrata, and their mixed formulation in treating knee osteoarthritis: A systematic review and network meta-analysis. Complement Ther Med. 2026;96:103256. PMID 41082950. https://pubmed.ncbi.nlm.nih.gov/41082950/
- Daily JW, Yang M, Park S. Efficacy of Turmeric Extracts and Curcumin for Alleviating the Symptoms of Joint Arthritis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. J Med Food. 2016;19(8):717-29. PMID 27533649. https://pubmed.ncbi.nlm.nih.gov/27533649/
- Kim LS, Axelrod LJ, Howard P, et al. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis Cartilage. 2006;14(3):286-94. PMID 16309928. https://pubmed.ncbi.nlm.nih.gov/16309928/
- Butawan M, Benjamin RL, Bloomer RJ. Methylsulfonylmethane: Applications and Safety of a Novel Dietary Supplement. Nutrients. 2017;9(3):290. PMID 28300758. https://pubmed.ncbi.nlm.nih.gov/28300758/
- Kasemsuk T, Saengpetch N, Sibmooh N, Unchern S. Improved WOMAC score following 16-week treatment with bromelain for knee osteoarthritis. Clin Rheumatol. 2016;35(10):2531-40. PMID 27470088. https://pubmed.ncbi.nlm.nih.gov/27470088/
- Henrotin Y, Pap T, Lieten S, et al. Oral enzyme combination therapy reduces systemic inflammation, urinary CTXII and pain in knee osteoarthritis: a proof-of-mechanism, randomised, crossover, double-blind, placebo-controlled trial. RMD Open. 2025;11(3):e005433. PMID 40803821. https://pubmed.ncbi.nlm.nih.gov/40803821/
- Javadi F, Ahmadzadeh A, Eghtesadi S, et al. The Effect of Quercetin on Inflammatory Factors and Clinical Symptoms in Women with Rheumatoid Arthritis: A Double-Blind, Randomized Controlled Trial. J Am Coll Nutr. 2017;36(1):9-15. PMID 27710596. https://pubmed.ncbi.nlm.nih.gov/27710596/
- Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020;72(2):220-233. PMID 31908163. https://pubmed.ncbi.nlm.nih.gov/31908163/
- Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-1589. PMID 31278997. https://pubmed.ncbi.nlm.nih.gov/31278997/
- Fransen M, McConnell S, Harmer AR, et al. Exercise for osteoarthritis of the knee. Cochrane Database Syst Rev. 2015;1:CD004376. PMID 25569281. https://pubmed.ncbi.nlm.nih.gov/25569281/
- Messier SP, Newman JJ, Scarlett MJ, et al. Changes in Body Weight and Knee Pain in Adults With Knee Osteoarthritis Three-and-a-Half Years After Completing Diet and Exercise Interventions. Arthritis Care Res (Hoboken). 2022;74(4):607-616. PMID 34369105. https://pubmed.ncbi.nlm.nih.gov/34369105/
- National Center for Complementary and Integrative Health. Glucosamine and Chondroitin for Osteoarthritis: What You Need To Know. U.S. National Institutes of Health. https://www.nccih.nih.gov/health/glucosamine-and-chondroitin-for-osteoarthritis
